[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut de Recherches Cliniques de Montreal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":241},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,81,118,146,171,195,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100629537","prevalence-and-risk-factors-of-metabolic-associated-hepatic-steatosis-in-individuals-living-with-type-1-diabetes-100629537",false,"NCT07475962","Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes","STEA-DT1","Inclusion Criteria:\n\n* Individuals ≥ 18 years of age.\n* A clinical diagnosis of type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) for at least one year, as per the investigators' clinical judgment (confirmatory C-peptide and antibodies will not be required).\n\nExclusion Criteria:\n\n* Alcohol consumption exceeding 20g per day in women or 30g per day in men.\n* Known chronic liver disease (including viral, drug-induced, Wilson disease, deficit in alpha-1-antirypsin, hemochromatosis, autoimmune hepatitis, etc.).\n* Evidence of cirrhosis based on a result of liver biopsy, or history of portal hypertension presented by ascites, hepatic encephalopathy or varices.\n* History of use of medications known to induce liver steatosis, including corticosteroids, high-dose estrogens, tamoxifen, methotrexate, amiodarone, or tetracycline.\n* Ongoing pregnancy.\n* Life expectancy of less than 5 years, as per investigators' clinical judgment.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","3 Days","OBSERVATIONAL","The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older living with type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) in Quebec.\n\nThe main questions it aims to answer are:\n\n1. What is the prevalence and severity of liver steatosis and fibrosis among people living with type 1 diabetes in Québec?\n2. Are there patients with type 1 diabetes who have advanced, undiagnosed stages of liver disease that require management but are missed by current standard care practices?\n\nResearchers will compare three participant subgroups based on adiposity (a control group without increased adiposity, an overweight group with increased adiposity, and an obesity group with increased adiposity) to see if the prevalence and severity of hepatic steatosis and fibrosis are highest in the obesity group and lowest in the control group. They will also explore if variables and potential risk factors associated with liver disease differ across these subgroups.\n\nParticipants will attend a single study visit where they will be asked to:\n\n* Provide clinical data through laboratory analyses.\n* Undergo specific clinical procedures.\n* Complete validated questionnaires.",[25,26,27,28,29],"Type 1 Diabetes","Liver Steatoses","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Liver Fibrosis","Latent Autoimmune Diabetes in Adult (LADA)",[31,32,33,34,35,36],"MASLD","Liver steatosis","Liver fibrosis","LADA","Body composition","Type 1 diabetes","NOT_YET_RECRUITING","2026-03-19",{"date":40,"type":41},"2026-03-23","ACTUAL",{"date":43,"type":20},"2026-04-01",{"date":45,"type":20},"2027-05-30",{"name":47,"class":48},"Institut de Recherches Cliniques de Montreal","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100630704","effect-of-ambient-temperature-on-blood-glucose-and-insulin-absorption-in-adults-with-type-1-diabetes-100630704","NCT07491133","Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes","Effect of Ambient Temperature on Insulin Absorption and Change in Blood Glucose Levels in Individuals With Type 1 Diabetes","T1Temp","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes for more than 2 years\n* Ability to provide verbal and written informed consent\n* Ability to speak and understand French\n\nExclusion Criteria:\n\n* Recent and\u002For unstable health condition (less than 3 months) prior to enrolment\n* Any viral infection at time of participation\n* Chronic illness other than type 1 diabetes (for example: pulmonary disease, cardiovascular disease, cancer)\n* Health condition not controlled by medication\n* Pregnancy or breastfeeding (for female participants)\n* Any other health condition deemed to pose undue health risks during participation in the study","45 Years",{"count":59,"type":20},30,"INTERVENTIONAL",[62],"NA","The goal of this clinical trial is to learn how different temperatures affect blood sugar levels in adults with type 1 diabetes. Climate change is causing more extreme hot and cold weather, and people with type 1 diabetes may be at higher risk during these temperature changes. The main questions it aims to answer are:\n\n* Do different temperatures (cold, normal, or hot) change blood sugar levels in people with type 1 diabetes?\n* How does temperature affect insulin absorption in the body?\n\nResearchers will compare three different temperature conditions to see how each affects blood sugar levels and insulin in the body.\n\nParticipants will:\n\n* Complete a screening visit with body measurements and questionnaires\n* Attend 3 separate study visits, each in a different temperature setting:\n* Cold room (10°C\u002F50°F)\n* Normal room temperature (23°C\u002F73°F)\n* Hot and humid room (36°C\u002F97°F with 65% humidity)\n* Sit for 2 hours in each temperature condition while researchers monitor their blood sugar, heart rate, and body temperature\n* Wear a continuous glucose monitor for 48-72 hours before each visit\n* Keep a diary of food, sleep, and activity for 24 hours before and after each visit\n\nEach temperature visit is separated by at least 3 days. The study helps researchers understand if people with type 1 diabetes need special guidance for managing their blood sugar during extreme weather.",[65],"Type 1 Diabetes Mellitus",[36,67,68,69,70,71],"Insulin absorption","Temperature exposure","Blood glucose","Continuous glucose monitoring","Hypoglycemia","2026-03-18",{"date":74,"type":41},"2026-03-24",{"date":76,"type":20},"2026-03",{"date":78,"type":20},"2027-07",{"name":47,"class":48},1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":16,"minAge":57,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":60,"phases":92,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":80},"100399795","targeting-risk-factors-for-diabetes-in-subjects-with-normal-blood-cholesterol-using-omega-3-fatty-acids-100399795","NCT04485871","Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids","White Adipose Tissue LDL Receptors and Omega-3 as Modulators of the Risk for Type 2 Diabetes in Subjects With Normal Plasma LDL Cholesterol","Inclusion Criteria:\n\nMen and post-menopausal women:\n\n* Having a body mass index (BMI= 25-40 kg\u002Fm2)\n* Aged between 45 and 74 years\n* Having confirmed menopausal status (FSH ≥ 30 U\u002Fl)\n* Non-smoker\n* Sedentary (less than 2 hours of structured physical exercise (ex: sports club) per week)\n* Low alcohol consumption: less than 2 alcoholic drinks\u002Fday\n\nExclusion Criteria:\n\n* Plasma LDL cholesterol \\> 3.5 mmol\u002FL (i.e. \\> 75th percentile in a Canadian population).\n* Elevated risk of cardiovascular disease (≥ 20% of calculated Framingham Risk Score) who would require immediate medical intervention by lipid-lowering agents.\n* Prior history of cardiovascular events (like stroke, transient ischemic attack, myocardial infarction, angina, heart failure…)\n* Systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg\n* Type 1 or 2 diabetes or fasting glucose \\> 7.0 mmol\u002FL\n* Prior history of cancer within the last 3 years\n* Thyroid disease - untreated or unstable\n* Anemia - Hb \\\u003C 120 g\u002FL\n* Renal dysfunction or plasma creatinine \\> 100 µmol\u002FL\n* Hepatic dysfunction - AST\u002FALT \\> 3 times normal limit\n* Blood coagulation problems (i.e. bleeding predisposition)\n* Autoimmune and chronic inflammatory disease (i.e. celiac, inflammatory bowel, Graves, multiple sclerosis, psoriasis, rheumatoid arthritis, and lupus).Known history of difficulties accessing a vein\n* Claustrophobia\n* Sleep apnea\n* Seizures\n* Concomitant medications: Hormone replacement therapy (except thyroid hormone at a stable dose), systemic corticosteroids, anti-psychotic medications and psycho-active medication, anticoagulant or anti-aggregates treatment (Aspirin, NSAIDs, warfarin, coumadin..), adrenergic agonist, anti-hypertensive drugs, weight-loss medication, lipid lowering medication\n* Known substance abuse\n* Already taking more than 250 mg of omega-3 supplements (EPA\u002FDHA) per day\n* Allergy to seafood or fish\n* Allergy to Xylocaine\n* Unable to eat the components of the high fat meal (croissant, cheese, bacon, brownies)\n* None compliance to the study requirements (i.e. not being fasting) or cancellation of the same scheduled testing visit more than once.\n* Lack of time to participate in the full length of the study (33 weeks)\n* Have exceeded the annual total allowed radiation dose (like X-ray scans and\u002For tomography in the previous year or in the year to come) according to the physician's judgement.\n* All other medical or psychological conditions deemed inappropriate according to the physician",true,"74 Years",{"count":91,"type":20},48,[62],"Every 3 minutes a new case of diabetes is diagnosed in Canada, mostly type 2 diabetes (T2D) increasing the risk for heart disease. T2D and heart disease share many common risk factors such as aging, obesity and unhealthy lifestyle.\n\nParadoxically however, while lowering blood LDL, commonly known as \"bad cholesterol\", is protective against heart disease, research over the past 10 years have shown that the lower is blood LDL, the higher is the chance of developing T2D. This phenomena is happening whether blood LDL is lowered by a common drug against heart disease called Statins, or by being born with certain variations in genes, some of which are very common (\\~80% of people have them).\n\nTo date, it is unclear why lowering blood LDL is associated with higher risk for diabetes, and whether this can be treated naturally with certain nutrients.\n\nInvestigators believe that lowering blood LDL by forcing LDL entry into the body tissue through their receptors promotes T2D. This is because investigators have shown that LDL entry into human fat tissue induces fat tissue dysfunction, which would promote T2D especially in subjects with excess weight.\n\nOn the other hand, investigators have shown that omega-3 fatty acids (omega-3) can directly treat the same defects induced by LDL entry into fat tissue. Omega-3 is a unique type of fat that is found mostly in fish oil.\n\nThus the objectives of this clinical trial to be conducted in 48 subjects with normal blood LDL are to explore if:\n\n1. Subjects with higher LDL receptors and LDL entry into fat tissue have higher risk factors for T2D compared to subjects with lower LDL receptors and LDL entry into fat tissue\n2. 6-month supplementation of omega-3 from fish oil can treat subjects with higher LDL receptors and LDL entry into fat tissue reducing their risk for T2D.\n\nThis study will thus explore and attempt to treat a new risk factor for T2D using an inexpensive and widely accessible nutraceutical, which would aid in preventing T2D in humans.",[95,96,97,98],"Type 2 Diabetes","Inflammation","Insulin Sensitivity\u002FResistance","Fatty Acids, Omega-3",[100,101,102,103,104,105,106,107,108],"Proprotein Convertase Subtilisin \u002F kexin Type 9 (PCSK9)","NLRP3 inflammasome","Eicosapentaenoic acid (EPA)","Docosahexaenoic acid (DHA)","White adipose tissue","Fat metabolism","ApoB-lipoproteins","LDL receptors (LDLR)","Cluster of differentiation 36 (CD36)","RECRUITING","2026-03-11",{"date":112,"type":41},"2026-03-12",{"date":114,"type":41},"2019-12-19",{"date":116,"type":20},"2027-05-31",{"name":47,"class":48},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":80},"100459105","glycemic-variations-during-the-menstrual-cycle-in-women-with-type-1-diabetes-100459105","NCT05258292","Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes","Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes: the GLYMETY Study","GLYMETY","Inclusion Criteria:\n\n1. Females aged 18 to 50 living in Canada.\n2. Clinical diagnosis of type 1 diabetes or latent autoimmune diabetes in adults (LADA) for at least one year.\n3. Using insulin pump therapy, multiple daily injections or automated insulin delivery systems for at least 3 months.\n4. Using a continuous glucose monitoring (CGM) system.\n5. Having at least one menses in the last 40 days.\n6. Accepting to share CGM data with the research team and if applicable insulin pump data.This access will be limited to the study period.\n7. Having a smartphone or tablet to follow menstrual cycles.\n8. Stable weight (less than 5% variation in the last 3 months).\n\nExclusion Criteria:\n\n1. Using a hormonal contraception method that eliminates menses (Depo Provera, progestin intrauterine device, extented-cycle regimen with birth control pill)\n2. Using regular insulin (Entuzity U500, Novolin ge Toronto or Humulin R).\n3. Clinically significant nephropathy (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2, planned or on dialysis) or neuropathy (e.g., known uncontrolled gastroparesis) as judged by the investigator.\n4. Recent (\\\u003C 6 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery).\n5. Anticipated therapeutic change (including change of insulin type and\u002For type of CGM sensor, insulin pump or AID (automated insulin device) system) between admission and end of the study.\n6. Anticipated change in contraception method or plan to begin or stop a contraceptive method.\n7. Anticipated need to use acetaminophen during the study period at a dose above 1g every 6 hours.\n8. Pregnancy (ongoing or current attempt to become pregnant)\n9. Breastfeeding\n10. Uncontrolled thyroid disease (TSH should be in target range and treatment stable for at least 6 weeks).\n11. Severe hypoglycemic episode within two weeks of screening\n12. Severe hyperglycemic episodes requiring hospitalization in the last 3 months.\n13. Current use of glucocorticoid medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®)\n14. Agents affecting gastric emptying (Motilium®, Victoza®, Ozempic®, Trulicity®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, Prandase®, DPP-4 inhibitors) unless at a stable dose for 3 months and without anticipated change during the study.\n15. Current use of SGLT-2 inhibitors unless at a stable dose for at least 3 months, without anticipated change during the study and appropriate ketone testing is performed.\n16. Other serious medical illnesses which likely interfere with study participation or with the ability to complete the study by the judgment of the investigator.\n17. Anticipation of a significant change in exercise or diet regimen between admission and end of the study (i.e., starting or stopping an organized sport; planned significant diet change).\n18. Anticipated radiologic examination incompatible with CGM wear for more than 10 days between admission and end of the study (e.g., repeated MRI).\n19. In the opinion of the investigator, a participant who is unable or unwilling to complete the study.\n20. If taking medication for hypothyroidism, no change of dose (Levothyroxin) in the last 6 weeks.","FEMALE","50 Years",{"count":129,"type":20},86,"In clinical practice, women living with type 1 diabetes frequently report that insulin requirements change across the menstrual cycle. Consequently, glycemic fluctuations are observed. This phenomenon could be explained by a decrease in insulin sensitivity during the second half of the menstrual cycle (luteal phase).\n\nOverall, despite an important proportion of women reporting glycemic and\u002For insulin variations across the menstrual cycle, studies to date have involved small sample sizes, and have had inconsistent results. The objective of this study will be to study glycemic fluctuations across the menstrual cycle using CGM data, alongside insulin data, in a large sample of women.",[132],"Type1diabetes",[134,70,135,136,137],"Menstrual cycle","Insulin dose","Physical activity","Food intake","2026-03-03",{"date":140,"type":41},"2026-03-05",{"date":142,"type":41},"2022-05-02",{"date":144,"type":20},"2026-05-31",{"name":47,"class":48},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":88,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":60,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100617727","feasibility-and-adoption-of-a-screening-program-for-t1d-relatives-in-canada-100617727","NCT07322380","Feasibility and Adoption of a Screening Program for T1D Relatives in Canada","The FEDERATE-CAN Trial - FEasibility and aDoption of a scrEening pRogrAm for T1d rElatives in CANada","FEDERATE","Inclusion Criteria:\n\n* Males and females ≥18 years old living in the Québec province\n* Having a FDR living with T1D (parents, siblings or offspring)\n* Willing to adhere to follow-up care if screened positive\n\nExclusion Criteria:\n\n* Having a diagnosis of T1D\n* Pregnancy (ongoing or current attempt to become pregnant)\n* Current or future expected use of glucocorticoid medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®) or any systemic immunosuppressive agents\n* Planned or recent (\\\u003C 6 weeks) monoclonal antibodies treatment, immunoglobulin perfusions or plasmapheresis.\n* Other serious medical illness likely to interfere with study participation or with the ability to complete the study by the judgment of the investigator",{"count":155,"type":20},1000,[62],"The aim of this study will be to evaluate the feasibility of an autoantibody-based type 1 diabetes screening program for first degree relatives of people living with type 1 diabetes within the province of Quebec. Feasibility of follow-up strategies of \"at-risk\" individuals will also be assessed.\n\nThis project will be divided into two phases, with the aim to evaluate:\n\n1. The feasibility of a IAb (islet antibody)-based screening process for first degree relatives of people living with type 1 diabetes (T1D).\n2. The feasibility of two approaches for follow-up monitoring in case of positive screening: centralized (within the organization) and decentralized approach (relying on individuals' healthcare providers), in the Quebec province setting.\n\nParticipants will come to the laboratory for blood sample collection, medical history and genetic risk score assessment, as well as anthropometric and cutaneous advanced glycated end (AGE) products measurements. A series of questionnaires will be completed.\n\nAfter screening results are obtained (i.e., presence or absence of IAbs), a virtual visit will be conducted to communicate results to participants.\n\nA positive result for IAb will warrant a second test for confirmation , using WBD within 3 months of initial screening.\n\nAfter IAb positivity confirmation, participants will be invited to participate in phase 2 of this project (monitoring). Participants will be given the opportunity to select either a centralized or decentralized path for study monitoring.\n\nFollow-up will be dependent of the stage of T1D:\n\n* Participants in pre-stage 1 or stage 1 (2 or more positive IAbs without dysglycemia) T1D will receive a follow-up phone call six months after the initial screening.\n* Participants in stage 2 (2 or more positive IAbs with dysglycemia) will be contacted one month after screening.",[159],"Type 1 Diabetes (T1D)",[161,162],"screening","type 1 diabetes","2026-03-02",{"date":165,"type":41},"2026-03-04",{"date":167,"type":20},"2026-04-05",{"date":169,"type":20},"2028-03-31",{"name":47,"class":48},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":60,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},"100568604","updating-preventive-and-treatment-guidelines-for-hypoglycemia-in-individuals-living-with-type-1-diabetes-100568604","NCT06683391","Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living With Type 1 Diabetes","Updating pReventive and Treatment guidelinEs for Mild hypOglycemia in Individuals Living With Type 1 Diabetes During the erA of Continuous gLucose Monitoring: The REMODAL Trial","REMODAL","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Clinical diagnosis of Type 1 diabetes for at least 1 year\n* Currently treated with multiple daily insulin injections (MDI), continuous subcutaneous insulin infusion (CSII), or automated insulin delivery (AID) systems\n* HbA1c level below 9.0%\n* Equal distribution of male and female participants, as well as MDI\u002FCSII and AID users\n\nExclusion Criteria:\n\n* Gastroparesis\n* Significant cardiac rhythm abnormalities\n* Clinically significant microvascular complications such as nephropathy (eGFR \\\u003C 40 ml\u002Fmin) or severe proliferative retinopathy\n* Diagnosis of epilepsy\n* Pregnancy or currently breastfeeding\n* Severe hypoglycemic episode within 1 month prior to inclusion\n* Macrovascular events or uncorrected hypokalemia (K+ \\\u003C 3.5 mmol\u002FL) within 3 months prior to inclusion\n* Anticipated treatment changes during the trial period\n* Inability to provide informed consent",{"count":180,"type":20},32,[62],"The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol\u002FL) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \\\u003C 4.0 mmol\u002FL). The goal is to reduce hypoglycemia frequency and improve quality of life, while minimizing caloric intake and rebound hyperglycemia.",[25],[162,185],"hypoglycemia","2025-02-24",{"date":188,"type":41},"2025-02-25",{"date":190,"type":41},"2025-02-06",{"date":192,"type":20},"2027-12-31",{"name":47,"class":48},2,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":22,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},"100341027","registry-of-patients-living-with-type-1-diabetes-100341027","NCT03720197","Registry of Patients Living With Type 1 Diabetes","Registry of Individuals With Type 1 Diabetes Living in Canada: The BETTER Registry","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes\n* Living in Canada\n\nExclusion Criteria:\n\n* Type 2 diabetes\n* Gestational diabetes",{"count":203,"type":20},6000,"10 Years","A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes living in Canada will be established. The objective of this registry will be to measure the frequency and the severity of episodes of hypoglycemia. Participants will be invited to answer questionnaires about the frequency of their hypoglycemic episodes, their fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin therapy, nutrition, exercise, etc.), etc.\n\nParticipation to the registry is divided in 3 phases. The first phase is mandatory for all participants. Phases 2 and 3 are optional.",[65],{"date":188,"type":41},{"date":209,"type":41},"2019-02-20",{"date":211,"type":20},"2027-03-31",{"name":47,"class":48},7,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":222,"targetDuration":224,"studyType":22,"phases":4,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},"100446938","identification-of-dysglycemia-with-continuous-glucose-monitoring-to-assess-clinical-evolution-in-cystic-fibrosis-100446938","NCT05099939","Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis","Identification of Dysglycemia With Continuous Glucose Monitoring: A Prospective Study to Assess the Relationship With Clinical Evolution in Cystic Fibrosis","ProspeC-F","Inclusion Criteria:\n\n* Have cystic fibrosis\n* Be 18 years of age or older\n* Have given clear and informed consent\n\nExclusion Criteria:\n\n* Receive pharmaceutical treatment for diabetes\n* Have had a lung or liver transplant\n* Participate in a randomized controlled trial for more than 3 months in parallel with this study\n* Currently pregnant\n* Patients under legal protection (for centers in France)",{"count":223,"type":20},121,"5 Years","Cystic fibrosis (CF)-related diabetes (CFRD) is the most important emerging complication after pulmonary complications. This specific form of diabetes is associated with an increased morbidity and mortality. CFRD prevalence at the age of 10 is 10% and reaches 40 to 50% in adulthood, while a similar percentage is afflicted with milder dysglycemia also called pre-diabetes abnormalities.\n\nIn order to identify patients at risk and to implement early therapeutic measures, an annual CFRD screening test is recommended for CF patients after 10 years of age. The standard 2-hour oral glucose tolerance test (OGTT) is the recommended screening test. However, this test is perceived by both patients and CF care teams as unpleasant while adding a significant burden and workload, resulting in screening rates lower than 50% in most centers. An ideal alternative test should be simpler, less invasive, more sensitive than an OGTT to establish risks for lung function and\u002For nutritional deterioration, and predict future CFRD risk. To date, compared to the OGTT, no alternative screening method has demonstrated its effectiveness. However, continuous glucose monitoring (CGM) is emerging as a possible alternative method.\n\nIn patients living with CF, CGM is easy to use and can identify early dysglycemia, which in turn, can predict increased risk of accelerated decline of pulmonary function and\u002For weight, higher risk of pseudomonas colonization, and future risk of CFRD. However, these observations are based on studies of small sample size with very limited prospective data. Furthermore, many of the multiple CGM metrics that have been standardized are based on the risk of complications associated with Type 1 and Type 2 Diabetes.\n\nThus, there is a need for prospective studies to identify the CGM metrics and the cut-off level that is relevant as a predictor of clinical deterioration and\u002For CFRD risk in CF. The identification of such CF-specific criteria would provide important information to target at-risk patients.",[227],"Cystic Fibrosis",[229,230,70,231],"Diabetes","Screening Test","Oral glucose tolerance test","2024-11-05",{"date":234,"type":41},"2024-11-06",{"date":236,"type":41},"2021-11-25",{"date":238,"type":20},"2026-07",{"name":47,"class":48},4,""]